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Objective: Gleason scores are often higher in radical prostatectomy (RP) specimens 
compared biopsy. Obese men are at a higher risk of death from prostate cancer therefore 
body mass index (BMI) may be an important predictor of Gleason sum upgrading. 
Methods: Between 1993 and 2014, 16,904 men underwent RP at Johns Hopkins and 
were eligible for this analysis. Upgrading was defined as any increase in Gleason sum 
and also as upgrading to a higher Gleason sum group: 2-6, 3+4, 4+3, and 8+. The 
association between higher BMI and upgrading was evaluated in multivariable-adjusted 
analyses. Separate analyses were performed in Caucasian and African American men and 
subsets of men with Gleason sum 6 disease, and in men with Gleason sum 6 with stage 
T1 or T2a, and PSA<10ng/mL. 
Results: In total, 21% of men upgraded to a higher Gleason sum at RP compared to at 
biopsy and 8% downgraded. After adjusting for factors that were associated with 
upgrading, men who were overweight had a 14% higher odds of upgrading (95% CI 1.03, 
1.25) and men who were obese had a 24% higher odds of upgrading (95% CI 1.10, 1.39). 
The association between BMI and upgrading was present among Caucasian, but not 
African American men (overweight OR = 0.90, 95% CI 0.64, 1.28); obese OR=1.01 95% 
CI 0.69, 1.49). In Caucasian and African American men with Gleason sum 6, stage T1 or 
T2a, and PSA <10ng/mL, there was a positive association between obesity and 
upgrading. Addition of BMI to multivariable-adjusted analyses did not significantly 
improve prediction of upgrading from Gleason sum 6 prostate cancer. 
iii 
 
Conclusions: Overweight and obesity were associated with a higher odds of upgrading 
between biopsy and RP in Caucasian men. In men with low risk disease, who may be 
eligible for active surveillance – Gleason 6 prostate cancer with PSA < 10 ng/mL and 
clinical stage of T1 or T2a – obesity was associated with an increased odds of upgrading 
in both African American and Caucasian men. Our work may inform treatment decision-
making for overweight and obese men, including African American obese men, newly 
diagnosed with prostate cancer. 
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For nearly 50 years, Gleason score grading of prostatic tumors has been used in 
clinical practice as a method for distinguishing between indolent and aggressive forms of 
prostate cancer. (1) Over this time period, modifications have been made to the Gleason 
grading system to keep up with improvements in the diagnosing of prostate cancer, and it 
remains an important predictor of long-term clinical outcomes such as recurrence and 
prostate cancer-specific mortality. (1) For these reasons, treatment decisions for the 
management of prostate cancer are often made based on the Gleason score from biopsy 
specimens at the time of diagnosis. One particular challenge in treatment decision-
making is the frequency in discrepancy between Gleason sums, a pathological indicator 
of tissue differentiation status that is prognostic, measured in biopsy and prostatectomy 
specimens. Prior studies investigating the correlation of Gleason score obtained from 
biopsy and surgical specimens have found that as many as 40% of men experience 
upgrading in Gleason sum of their prostate cancer. (2-5) These differences in Gleason 
sum between biopsy and surgical specimens have previously been attributed to missing 
the highest graded region of cancer during biopsy as well as inter- and intra-pathologist 
variation, and progression of tumor. (2-5) 
Upgrading is of particular concern for men with biopsy Gleason 6 prostate cancer, 
who because of their lower predicted risk of death from prostate cancer, may be weighing 
the risks versus benefits of active surveillance compared with immediate treatment with 
curative intent. (6,7) Yet, men with biopsy Gleason sum 6 disease have been found to be 
at the highest risk of upgrading. (8-10)  
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Here we studied the association between body fatness as measured by body mass 
index (BMI) and upgrading. The reason we focused on obesity is that higher BMI is 
associated with an increased risk of death from prostate cancer and is associated with 
larger prostate volume, higher blood plasma volume, and lower PSA levels. (11-14) As a 
result, higher BMI may be an important predictor of Gleason score upgrading between 
biopsy and prostatectomy. One study found that overweight and obese men were more 
likely to experience upgrading than those with BMI less than 25, however, the ability to 
stratify analyses based on race and Gleason score was limited by low sample size (15). 
Another study in European men found no relationship between BMI and Gleason score 
upgrading, and the authors acknowledge this may be due to a lower average BMI in their 
sample compared to American cohorts. (8) Two other studies investigating upgrading 
among men with Gleason 6 prostate cancer found associations with BMI, but again 
analyses were not stratified by race to investigate the effect of BMI separately among 
African American and Caucasian men. (16, 17)  
In the United States in 2012, nearly 75% of men aged 60 or older have a BMI 
greater than 25, and 32% were categorized as obese, which makes it even more important 
to understand the impact of BMI on biopsy findings. (18) Thus, we hypothesized that the 
likelihood of upgrading would be greater in men with higher compared with lower BMI 
even for the same biopsy Gleason sum disease. Further, we addressed whether the 
association between BMI and the odds of upgrading differed between black and white 






We conducted a retrospective cohort analysis of men with clinically-localized 
prostate cancer who underwent radical prostatectomy (RP) at Johns Hopkins Hospital 
between January 1, 1993, when PSA-based prostate cancer screening was fully routine in 
the US, and December 1, 2014. We excluded from the analysis men whose biopsy or 
prostatectomy specimens did not contain prostate cancer, Gleason sum was not available, 
or the prostate cancer had a histology other than adenocarcinoma (n=200). Men with 
missing or extreme values for height or weight were excluded (n=3,618). Men missing 
clinical tumor stage or pre-surgical PSA were excluded (n=430). Shown in Figure 1 are 
the exclusions, which left 16,904 men in the study population. 
Information on age, race, preoperative height, preoperative weight, any family 
history of prostate cancer, preoperative PSA, surgery year, clinical tumor stage (T1, T2a, 
T2b, T2c, and T3), biopsy Gleason score, pathologic stage, and Gleason score on radical 
prostatectomy was abstracted from the medical records. Number of biopsy cores taken, 
number of biopsy cores with cancer, and highest percentage of cancer of any core were 
also recorded in the established database when available. For men with Gleason sum 7 in 
the biopsy or in the prostatectomy specimen, we used the primary and secondary Gleason 
patterns to sub-classify them as having either 3+4 or 4+3 prostate cancer. 
The follow-up of this cohort was approved by the Institutional Review Board at 
the Johns Hopkins School of Medicine. This analysis was additionally approved by the 




Assessment of obesity 
Body mass index (BMI) was calculated as measured at their pre-surgery visit: 
weight in kilograms divided by the square of height in meters. We categorized the men as 
normal weight (<25 kg/m2), overweight (25 to < 30 kg/m2), and obese (≥30 kg/m2) (ref 
CDC). Only 30 men were considered to be underweight (BMI <18.5 kg/m2); they were 
included in the normal weight group. 
 
Assessment of upgrading and downgrading 
Upgrading Gleason sum between the biopsy and prostatectomy was defined two 
ways. First, upgrading was defined as having a higher Gleason sum in the prostatectomy 
specimen compared to biopsy. Nineteen men found to have Gleason 10 prostate cancer at 
biopsy were excluded because they were incapable of upgrading to a higher sum (Figure 
1). 
For the second definition, we first separated men into four biopsy Gleason sum 
groups: group 1 – 2 to 6; group 2 – 3+4; group 3 – 4+3; and group 4 – 8 and higher. 
Then, the second definition was having a higher Gleason sum category in the 
prostatectomy specimen compared to biopsy. Downgrading was similarly defined: having 
a lower Gleason sum or lower Gleason sum group in the prostatectomy specimen than in 
the biopsy. 812 men were excluded from the second definition for upgrading because 
they were in the highest Gleason sum category (Gleason sum 8 or higher) at biopsy and 
therefore could not achieve the outcome. Records for four men did not have primary and 
secondary scores (three with Gleason sum 7 and one with sum 5) and therefore they were 
dropped from all analyses using Gleason sum groups to determine upgrading (Figure 1). 
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These two definitions of upgrading (or downgrading) do not always correspond; 
for example, a man diagnosed with 3+4 disease on biopsy, but who was found to have 
4+3 disease in the prostatectomy specimen would meet criteria for upgrading under the 
second definition but not for the first. Conversely, a man with Gleason sum 5 from 
biopsy and sum 6 from prostatectomy would be considered to have upgraded according 
to the first definition but not the second.  
 
Statistical Analysis 
To characterize the men and to begin to identify potentially confounding factors, 
we calculated the mean or prevalence of demographic and clinical characteristics among 
the three BMI categories (<25, 25 to <30, and ≥30 kg/m2). We determined the statistical 
significance of any differences in the means or prevalances across BMI categories using 
linear regression for continuous variables (age at diagnosis, pre-surgery PSA, year of 
surgery, biopsy Gleason sum) and multinomial logistic regression for categorical 
variables (race, clinical tumor stage, change in Gleason sum, change in Gleason Group).  
We included in the analysis only men who were upgraded or who had no change. 
Using the first outcome definition, men who were downgraded based on sum were 
excluded as were men with Gleason sum 10 because they could not be upgraded, which 
left 15,582 men in the analysis. Using the second outcome definition, men who were 
downgraded based on category were excluded as were men with Gleason sum group 4 
(Gleason sums 8 to 10) because they could not be upgraded, which left 14,871 men in the 
analysis. To evaluate the association between BMI and upgrading using either the first or 
second outcome definition (versus no change), we entered into a logistic regression 
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model indicator variables for overweight (25 to <30 kg/m2) and obese (≥30 kg/m2); the 
reference group was normal weight (<25 kg/m2). We present unadjusted and 
multivariable-adjusted (race, clinical tumor stage, biopsy Gleason sum, pre-surgery PSA 
[transformed using log2], age at surgery, year of surgery) odds ratios (ORs) and 95% 
confidence intervals. We considered the influence of additionally adjusting for number of 
biopsy cores taken, number of biopsy cores with cancer, and highest percentage of cancer 
in those with available information. We considered the influence of 2005 change in the 
Gleason grading system on the results by stratifying the main analysis using a cutpoint of 
2005 year of surgery. 
Because African-American men are more likely to be upgraded, we repeated the 
main analyses separately in African-American and in Caucasian men. We expanded these 
analyses to simultaneously model upgrading by one or by two or more Gleason sum 
levels (e.g., 6 to 7) and downgrading (both versus no change) using multinomial logistic 
regression separately in African-American and in Caucasian men. 
We performed additional sub-analyses for BMI and upgrading separately in 
African-American and Caucasian men to inform decision-making about active 
surveillance for obese men: (1) men with biopsy Gleason sum 6 disease, (2) men with 
low clinical tumor stage (≤T2a) and PSA (<10 ng/mL), and 3) men with both (1) and (2); 
downgrading was not investigated because of small sample size.  
We calculated the area under the receiver operating characteristic (ROC) curve 
(AUC), to assess whether BMI added to the predictive capacity of demographic and 
clinical factors for upgrading among men with biopsy Gleason sum 6 prostate cancer and 
men with Gleason 6 prostate cancer, T1 or T2a stage, and PSA < 10 ng/mL. All analyses 
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were performed in Stata version 13.1 (StataCorp, College Station, TX). Statistical tests 
were two-sided and p<0.05 was considered to be statistically significant. 
 
RESULTS 
Baseline Patient Characteristics 
Demographic and clinical characteristics for the 16,904 men in the study 
population are reported in Table 1. The number of men excluded for each of the reasons 
as described above are displayed in Figure 1. The majority of the men in the study 
population were Caucasian (86%), had T1 disease (73%), biopsy Gleason 6 prostate 
cancer (68%), and with median PSA of 5.4 ng/mL. Of those with T1 disease, 76 were 
staged as either T1a or T1b, and 12,182 (99%) had T1c prostate cancer. 
55% of the men were overweight and 19% were obese. There were statistically 
significant differences in racial composition, surgical year, and biopsy Gleason score 
between men in different BMI categories. With increasing BMI group, the sample 
contained a higher percentage of African American men, underwent surgery later, and 
had higher proportions of Gleason 7 prostate cancer in biopsy specimens. Distribution of 
clinical tumor stage from DRE across BMI groups appeared similar. Based on Gleason 
sum, 21% of the men were upgraded and 8% were downgraded. Based on Gleason sum 
group,  24% were upgraded, and 8% were downgraded. 
 
Association between BMI and upgrading 
The association between BMI and upgrading is reported in Table 2. Men who 
were overweight had a 12% higher odds of upgrading (95% CI 1.02, 1.23) based on 
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Gleason sum and those who were obese had a 15% higher odds of upgrading (95% CI 
1.03, 1.29) compared to those with a normal BMI (p-trend = 0.016). After adjusting for 
factors that were associated with upgrading (Table 2), men who were overweight had a 
14% higher odds of upgrading (95% CI 1.03, 1.25) and men who were obese had a 24% 
higher odds of upgrading (95% CI 1.10, 1.39) (p-trend < 0.001). The association between 
BMI and upgrading based on Gleason sum was present among Caucasian, but not African 
American men (overweight OR = 0.90, 95% CI 0.64, 1.28); obese OR=1.01 95% CI 0.69, 
1.49) (Table 3). 
The association between BMI and upgrading based on Gleason sum groups 
(Table 4) was consistent with the association for upgrading based on Gleason sum. Being 
overweight or obese was associated with an increased odds of upgrading to a higher 
Gleason sum group by 11% or 19%, respectively. As for upgrading based on Gleason 
sum, BMI was not associated with upgrading based on Gleason sum groups in African-
American men, but was positively associated in Caucasian men (Table 5). In the men 
with information, the results for BMI and upgrading were not notably different when 
adjusting for number of biopsy cores taken, number of cores with cancer, or the highest 
percentage of cancer of any core (data not shown). The main results for BMI and 
upgrading did not differ before and at or after 2005, when the modified Gleason grading 




Association between BMI and downgrading and upgrading separately in Caucasian and 
African American men 
The multivariable-adjusted association between BMI and downgrading and 
upgrading separately in Caucasian and African American men is shown in Tables 6 and 
7, respectively. Among only Caucasian men, being overweight was associated with 
increased odds of upgrading one level compared to those with a normal BMI, and 
marginally significant for upgrading two or more levels. Being overweight was possibly 
positively associated with downgrading (OR=1.13, 95% CI 0.96, 1.33). Being obese 
compared to normal BMI was associated with an increased odds of upgrading 1 level by 
22% (95% CI 1.07, 1.40) and 2 or more levels by 60% (95% CI 1.14, 2.25). 
In African American men, being overweight and obese were inversely associated 
with downgrading. BMI was not associated with upgrading 1 level, but we could not rule 
out that BMI was associated with upgrading 2 or more levels. 
 
Association between BMI and downgrading and upgrading separately in Caucasian and 
African American men with biopsy Gleason sum 6 Prostate Cancer 
Tables 8 and 9 show the multivariable-adjusted association between BMI and 
change in Gleason sum in Caucasian and African-American men with biopsy Gleason 6 
disease. In Caucasian men with Gleason 6 disease obesity was inversely associated with 
downgrading (OR=0.56, 95% CI 0.31, 1.00), while both overweight and obesity were 
positively associated with upgrading based on Gleason sum. In African American men 
with Gleason 6 disease, overweight and obesity appeared to be positively associated with 
upgrading; the number of men who were downgraded was too small to draw conclusions. 
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Table 10 shows the association between BMI and upgrading among African-American 
and Caucasian men with clinical tumor stage ≤T2a and PSA<10 ng/mL. Positive 
associations between obesity, but not overweight, and upgrading were observed in both 
racial groups. When additionally restricted to Gleason sum 6 disease, a possible positive 
association between obesity (compared with combined normal and overweight) and 
upgrading based on Gleason sum was observed in both racial groups. 
 
Does BMI add to the prediction of upgrading in men with biopsy Gleason sum 6 prostate 
cancer? 
For upgrading based on Gleason sum in Caucasian men with biopsy Gleason sum 
6 prostate cancer, the AUC for PSA, clinical tumor stage, age, and year of surgery was 
0.6650. When we added BMI, the AUC changed to 0.6652. ROC curves are shown in 
Figure 2. These results were similar in Caucasian and African American men with biopsy 
Gleason sum 6 prostate cancer. 
 
DISCUSSION 
In this retrospective study of 16,904 men who underwent prostatectomy at Johns 
Hopkins Hospital in 1993-2014 following a biopsy-confirmed diagnosis of prostate 
cancer, being overweight or obese was associated with an increased odds of upgrading to 
a higher Gleason sum. Taking into account factors that are associated with upgrading, 
overweight men had a 15% increased odds of and obese men had a 25% increased odds 
of upgrading. Our work may inform treatment decision-making for overweight and obese 
men newly diagnosed with prostate cancer.  
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After stratifying into groups based on race, the results for Caucasian men were 
very similar to results from the entire sample, which was expected since the population 
under study was 86% Caucasian. However, among African American men no 
associations between upgrading and the overweight and obese BMI categories were 
found. Therefore all further analyses were stratified by race to compare the associations 
between BMI category and upgrading in Caucasian and African American men. No prior 
studies were found that investigated the association of BMI with upgrading separately 
within African American men to compare findings. 
In multivariable-adjusted multinomial analyses, the odds ratios for overweight 
and obese BMI categories were stronger for upgrading two or more Gleason sum levels 
than upgrading one level for both Caucasian and African American men. Interestingly, in 
multinomial analyses, being overweight appeared to be associated with a decreased odds 
of downgrading in African American men, an association not seen among Caucasian 
men. Although the odds ratios did not meet statistical significance, obesity appeared to be 
associated with a decreased the odds of downgrading Gleason sum in both race groups. 
The study by Freedland and colleagues in 2007 had similar findings: being 
overweight was associated with an increased odds of upgrading between Gleason sum 
groups by 44% compared to BMI less than 25 and for obese men the odds were 89% 
higher. (15) These stronger odds ratios may be due to differences in the underlying 
populations, as their sample had a higher proportion of men with T2 or T3 disease (42% 
vs. 27%), had higher PSA (median 6.4 vs. 5.4), and worse biopsy Gleason sum (47% 
with Gleason 7 or higher vs. 30%). 
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Contrary to our results, a study from Tilki and colleagues in 2011 included BMI 
as a continuous covariate and did not find an association with upgrading between 
Gleason sum groups. (8) Of note, their sample was derived from a European cohort, 
which may have different screening and diagnosis practices than in the United States. 
In a study by Vora et al in a population with a high percentage of African 
American men (37%), they found that each 1 unit increase in BMI was associated with a 
3.6% increased odds of upgrading from low risk prostate cancer (p-value=0.02). (16) 
Another study by Truong and colleagues found that being obese increased odds of 
upgrading by 90% (p-value=0.047) in another cohort of men with low risk prostate 
cancer, however, race was not included in multivariable models as their sample was 
almost entirely Caucasian. (17)  
The positive association of higher BMI category with upgrading of Gleason sum 
or to a higher Gleason sum group is consistent with the hypothesis that upgrading may 
result from incomplete sampling of the highest graded portion of the tumor. As men with 
higher BMI tend to have larger prostates, the cores obtained from needle biopsy would 
represent a smaller percent of the prostate sampled, therefore increasing the chances of 
missing the worst tumor. (12)  
Predictive ability of BMI was explored in a sample of men with biopsy Gleason 
sum 6 prostate cancer. This population represents men for whom active surveillance may 
be considered based on previous long-term studies following men for progression of 
disease and death from prostate cancer. (6-7, 19) Within this sample, obesity compared to 
normal BMI was associated with an increased odds of upgrading, a relationship not seen 
in overweight versus normal BMI. When analyses were re-run in the same sample but 
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only including BMI as a binary variable at the cutoff for obesity (30 kg/m2), Caucasian 
men experienced a 15% increased odds of upgrading (95% CI: 1.00, 1.32) and obese 
African American men a 31% increased odds (95% CI: 0.92, 1.87) compared to their 
non-obese counterparts.  
A study by Sundi et al. investigated the association of obesity with worse 
pathological outcomes at the time of surgery, including increased Gleason sum, higher 
clinical tumor stage, or positive surgical margins and found that among 87 African 
American men, obesity was associated with an increased odds of upgrading by 24%, 
although it failed to reach significance (p-value=0.642) probably due to low sample size. 
This study also found a huge disparity in the location of the highest grade tumor within 
the prostate in African Americans compared to Caucasian men. African American men 
were much more likely to have their worst disease located in the anterior of the prostate, 
the furthest location from the point of entry for biopsy needles, which may explain in part 
why they are more likely to upgrade between timepoints compared to Caucasian men. 
(19) 
Addition of BMI to models with PSA, clinical tumor stage, age, and year of 
surgery did not improve the predictive capacity for upgrading to a higher Gleason sum. 
The study by Truong and colleagues explored the predictive ability of their multivariable 
model including PSA density, obesity, number of positive cores, and maximum core 
involvement in samples of men from the University of Wisconsin, University of Chicago, 
and University of Miami and found them to have areas under the curve of 0.753, 0.677, 
and 0.672, respectively. (17)  
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Due to the large sample size in this study, we were able to stratify analyses on 
race and investigate the association of higher BMI with upgrading of Gleason sum 
separately among African American and Caucasian men. Additionally, the large sample 
size allowed assessment of the relationship within different eras of time over the past 20 
years, when the prevalence of overweightness and obesity increased in the United States. 
(18) 
As this study was performed among men who underwent prostatectomy at Johns 
Hopkins Hospital, it is limited in its ability to extend findings to settings beyond large, 
academic cancer centers. Another limitation of the study was the limited information on 
number of positive cores found during biopsy, which indicates multi-focal prostate 
cancer, another characteristic that has been found to be associated with upgrading. 
Maximum percent involvement of any one core was also not considered in the main 
analyses due to missing data. Although sensitivity analyses were performed to compare 
the associations with upgrading before and after inclusion of these variables, it is not 
certain that they do not add important information to models. 
Additionally, men with Gleason 6 or lower with other low risk clinical features 
may not actually represent those eligible for active surveillance because everyone in the 
study sample underwent prostatectomy and the exact reason why surgery was indicated is 
not captured on a case-by-case basis. Also, all prediction analyses were performed within 






Overweight and obesity were associated with a higher odds of upgrading of 
Gleason sum between biopsy and prostatectomy in Caucasian men. In men with low risk 
prostate cancer, who may be eligible for active surveillance – Gleason 6 prostate cancer 
with PSA < 10 ng/mL and clinical stage of T1 or T2a – obesity was associated with an 
increased odds of upgrading in both African American and Caucasian men. Our work 
may inform treatment decision-making for overweight and obese men, including African 
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Table 2. Unadjusted and multivariable-adjusted associations between BMI categories and upgrading of 
Gleason sum from biopsy to prostatectomy, 1993-2014, Johns Hopkins Hospital. 
Upgrade in Gleason Sum (n=15,582) 
      Univariable Multivariable* 
Variable   n (# upgrade) OR (95% CI) OR (95% CI) 
BMI Category Normal 4,079 (886) Reference Reference 
  Overweight 8,572 (2,033) 1.12 (1.02, 1.23) 1.14 (1.03, 1.25) 
  Obese 2,931 (709) 1.15 (1.03, 1.29) 1.24 (1.10, 1.39) 
   p-trend = 0.016 p-trend < 0.001 
Race Caucasian 13,372 (3,044) Reference Reference 
  African-American 1,381 (378) 1.28 (1.13, 1.45) 1.38 (1.20, 1.57) 
  Other 829 (206) 1.12 (0.95, 1.32) 1.19 (1.01, 1.42) 
Clinical Tumor Stage T1 11,341 (2,512) Reference Reference 
  T2a 2,889 (726) 1.18 (1.07, 1.30) 1.58 (1.43, 1.75) 
  T2b 1,084 (302) 1.36 (1.18, 1.56) 1.95 (1.68, 2.28) 
  T2c 204 (70) 1.84 (1.37, 2.46) 2.27 (1.65, 3.13) 
  T3 64 (18) 1.38 (0.80, 2.38) 2.34 (1.28, 4.30) 
Biopsy Gleason Sum    0.44 (0.40, 0.47) 0.31 (0.28, 0.34) 
Pre-surgery PSA, log2   1.47 (1.40, 1.53) 1.61 (1.54, 1.69) 
Age at Surgery   1.03 (1.02, 1.03) 1.04 (1.03, 1.04) 
Year of Surgery   0.98 (0.97, 0.98) 1.02 (1.01, 1.03) 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 8. Multivariable-adjusted association* between BMI and change in Gleason sum in Caucasian 
men with biopsy Gleason 6 disease, 1993-2014, Johns Hopkins Hospital.  
Change from Gleason sum 6 among Caucasian men (n=9,977) 
      Downgrading (n=181) Upgrading (n=2,437) 
Variable   n # OR (95% CI) # OR (95% CI) 
BMI Category Normal 2,707 55 Reference 614 Reference 
  Overweight 5,555 111 1.13 (0.81, 1.57) 1,379 1.11 (0.99, 1.24) 
  Obese 1,715 15 0.56 (0.31, 1.00) 444 1.19 (1.03, 1.38) 
    p-trend = 0.126  p-trend = 0.016 
Clinical Tumor Stage T1 7,676 137 Reference 1,739 Reference 
  T2a 1,691 34 0.85 (0.57, 1.26) 473 1.74 (1.53, 1.97) 
  T2b 493 6 0.43 (0.18, 0.98) 175 2.25 (1.83, 2.76) 
  T2c 94 4 1.53 (0.53, 4.38) 40 2.68 (1.73, 4.16) 
  T3 23 0 zero # 10 2.96 (1.22, 7.19) 
Pre-surgery PSA, log2      0.90 (0.77, 1.05)  1.77 (1.67, 1.88) 
Age at Surgery     1.01 (0.99, 1.03)  1.04 (1.03, 1.05) 
Year of Surgery     0.84 (0.81, 0.87)   1.04 (1.03, 1.05) 
*From a multinomial logistic regression model and adjusted for all presented variables. 
 
 
Table 9. Multivariable-adjusted association* between BMI and change in Gleason sum in African-
American men with biopsy Gleason 6 disease, 1993-2014, Johns Hopkins Hospital.  
Change from Gleason sum 6 among African American men (n=920) 
      Downgrading (n=8) Upgrading (n=314) 
Variable   n # OR (95% CI) # OR (95% CI) 
BMI Category Normal 152 1 Reference 53 Reference 
  Overweight 527 6 2.19 (0.25, 19.52) 171 1.18 (0.57, 1.26) 
  Obese 241 1 0.79 (0.05, 13.23) 90 1.15 (0.74, 1.79) 
    p-trend = 0.756  p-trend = 0.286 
Clinical Tumor Stage T1 769 7 Reference 259 Reference 
  T2a 120 1 0.59 (0.07, 5.04) 40 1.10 (0.71, 1.70) 
  T2b 25 0 zero # 11 1.48 (0.63, 3.47) 
  T2c 6 0 zero # 4 3.92 (0.68, 22.69) 
  T3 0 0 omitted 0 omitted 
Pre-surgery PSA, log2      0.89 (0.43, 1.86)   1.77 (1.48, 2.12) 
Age at Surgery      1.13 (1.00, 1.27)   1.05 (1.02, 1.07) 
Year of Surgery       0.84 (0.72, 0.98)   1.03 (1.00, 1.06) 











Table 10. Multivariable-adjusted association* between BMI and upgrading in 
Caucasian and African-American men with clinical tumor stage ≤T2a and 
PSA<10 ng/mL, 1993-2014, Johns Hopkins Hospital. 
Upgrading from Gleason sum 6 among Caucasian men  
with ≤T2a and PSA<10 ng/mL (n=8,366) 
      Upgrading (n=1,817) 
Variable   n # OR (95% CI) 
BMI Category Normal 2,276 464 Reference 
  Overweight 4,662 1,020 1.06 (0.93, 1.20) 
  Obese 1,428 333 1.19 (1.01, 1.41) 
    p-trend = 0.035 
Clinical Tumor Stage T1 6,856 1,447 Reference 
  T2a 1,510 370 1.57 (1.37, 1.80) 
Pre-surgery PSA      1.20 (1.16, 1.23) 
Age at Surgery      1.04 (1.03, 1.05) 
Year of Surgery       1.05 (1.04, 1.06) 
Upgrading from Gleason sum 6 among African American men  
with ≤T2a and PSA<10 ng/mL (n=763) 
      Upgrading (n=233) 
Variable   n # OR (95% CI) 
BMI Category Normal 124 37 Reference 
  Overweight 438 128 0.91 (0.58, 1.42) 
  Obese 201 68 1.22 (0.74, 2.00) 
    p-trend = 0.265 
Clinical Tumor Stage T1 663 204 Reference 
  T2a 100 29 0.99 (0.61, 1.61) 
Pre-surgery PSA      1.21 (1.12, 1.32) 
Age at Surgery      1.04 (1.02, 1.06) 
Year of Surgery       1.03 (1.00, 1.06) 



















Table 11. Multivariable-adjusted association* between BMI and upgrading in 
Caucasian and African-American men with biopsy Gleason sum 6 disease, clinical 
tumor stage ≤T2a, and PSA<10 ng/mL, 1993-2014, Johns Hopkins Hospital. 
Upgrading from Gleason sum 6 among Caucasian men 
with ≤T2a and PSA<10ng/mL (n=8,366) 
      Upgrading (n=1,817) 
Variable   n # OR (95% CI) 
BMI Category** Not obese 6,938 1,484 Reference 
  Obese 1,428 333 1.15 (1.00, 1.32) 
Clinical Tumor Stage T1 6,856 1,447 Reference 
  T2a 1,510 370 1.57 (1.37, 1.80) 
Pre-surgery PSA      1.20 (1.16, 1.23) 
Age at Surgery      1.04 (1.03, 1.05) 
Year of Surgery       1.05 (1.04, 1.06) 
Upgrading from Gleason sum 6 among African American men  
with ≤T2a and PSA<10ng/mL (n=763) 
      Upgrading (n=233) 
Variable   n # OR (95% CI) 
BMI Category** Not Obese 562 165 Reference 
  Obese 201 68 1.31 (0.92, 1.87) 
Clinical Tumor Stage T1 663 204 Reference 
  T2a 100 29 0.99 (0.61, 1.61) 
Pre-surgery PSA      1.21 (1.12, 1.31) 
Age at Surgery      1.04 (1.02, 1.06) 
Year of Surgery       1.03 (0.99, 1.06) 
*Adjusted for all presented variables 

















Figure 1. Inclusion and exclusion of subjects in analyses, 1993-2014, Johns Hopkins 
Hospital. 
Abbreviations: JHH, Johns Hopkins Hospital; RP, radical prostatectomy; GS, Gleason 
sum; lbs, pounds; BMI, body mass index; PSA, prostate-specific antigen. 
This figure shows the numbers and reasons for exclusion from analyses using each 






Figure 2. Receiver operating characteristic curves for men with Gleason sum 6 prostate 
cancer in Caucasian and African American men, 1993-2014, Johns Hopkins Hospital. 
Models including age, year of surgery, pre-surgery PSA, and clinical tumor stage, with 
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The percentage of obese men in the sample increased from 9.9% in 1993 to 26.7% 
in 2014 (Figure 3, next page). A complementary decrease was observed in the proportion 
of men with BMI less than 25 from 34% to 23% over the same period. Trends over time 
were also observed in the proportion of men with Gleason 6 prostate cancer, which 
appears to increase in the sample over the first 5 years to 80%, then decrease to less than 
50% more recently. Since 2000, only 17 men have had prostatectomies for prostate 
cancers graded with a combined Gleason sum of 5 or less within the sample. As such, the 
proportions of men with Gleason 7 or higher prostate cancers increased gradually over 
the course of study. Over time, the proportion of men with T1 disease in the sample has 
increased as by definition these cancers are not felt during DRE or seen with ultrasound. 
As expected, the percentages of men with T2 or T3 prostate cancers have decreased over 
the period during which PSA screening has become popular. Lastly in Figure 3, there 
have been no stark changes in median PSA but the variability appears to be lower from 










































Figure 3. Trends in the proportions of selected characteristics over time, 1993-2014, 
Johns Hopkins Hospital. 
The proportion of men of normal weight decreases over time, as does those diagnosed 
with Gleason sum 6 prostate cancer. The proportion of men with stage T1 disease 
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